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Résumé en
anglais
The hepatitis C virus (HCV) envelope protein 2 (E2) interacts in vitro with the
interferon alpha (IFN-alpha)-inducible double-stranded RNA-activated protein
kinase, suggesting a possible mechanism by which HCV may evade the antiviral
effects of IFN-alpha. Variability in the part of the HCV E2 gene encoding the
carboxy-terminal part of the protein, which includes the interaction domain (E2-
PePHD), was explored in 25 patients infected with HCV genotype 1b and receiving
IFN-alpha therapy. PCR products were generated and sequenced for 15 patients
with a sustained response and for 10 patients with no virological response after
treatment with IFN-alpha and ribavirin. PePHD amino acid sequences were obtained
for isolates from serum collected before and during treatment, after 2 months in
responders, and after 6 months in nonresponders. Quasispecies analysis of the
pretreatment PePHD region was performed for isolates from patients displaying
amino acid substitutions in this domain on direct sequencing. The E2-PePHD
sequence was highly conserved in both resistant and susceptible genotype 1b strains
and was identical to the prototype HCV type J sequence. No significant emergence
of PePHD mutants during therapy was observed in our clonal analysis, and sporadic
mutations and treatment outcomes were not found to be correlated. The PePHD
sequence before or during treatment cannot be used to predict reliably the outcome
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